Vera Therapeutics (VERA) stock is in focus after the company reached agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial of atacicept in IgA nephropathy.

At a share price of $34.24, Vera Therapeutics has seen the 7 day share price return rise 7.84%, although the 90 day share price return is down 12.92% and the year to date share price return is down 29.58%. The 1 year total shareholder return of 56.70% and 3 year total shareholder return of 166.05% indicate stronger longer term performance as the market reacts to clinical milestones such as the updated ORIGIN 3 eGFR analysis plan.

If this kind of clinical update has your attention, it may be a useful time to broaden your watchlist with other healthcare opportunities using our 41 healthcare AI stocks.

With Vera Therapeutics trading at $34.24 and both its implied intrinsic value and analyst price target above the current share price, investors now have to ask whether a mispricing still exists or if the market is already factoring in future growth.

DCF valuation: how the SWS model frames Vera Therapeutics stock

The SWS DCF model estimates a future cash flow value for Vera Therapeutics of $440.11 per share, compared with the last close of $34.24. This points to a very large gap between modelled value and current trading levels.

The DCF approach projects a stream of future cash flows for Vera Therapeutics, then discounts those cash flows back to today using a required rate of return. The result is a single estimate of what those future cash flows could be worth in today’s dollars. This can then be compared directly to the current share price.

For a clinical stage biotech like Vera Therapeutics that currently reports no revenue and a net loss of $368.953m, this kind of model leans heavily on assumptions about future revenue growth, margins, and the timing of potential profitability. The DCF output therefore sits alongside other information, such as the company’s clinical milestones and analyst forecasts. It is one way for you to frame where the current $34.24 share price stands against a long term cash flow view.

Result: DCF Fair value of $440.11 (UNDERVALUED)

However, the DCF case for Vera Therapeutics can be challenged if key clinical programs face delays or setbacks, or if ongoing net losses pressure future funding options.

Another view on Vera Therapeutics stock value

While the SWS DCF model points to a very large potential upside for Vera Therapeutics, the P/B ratio tells a different story. At 4.9x book value compared with 2.4x for the US Biotechs industry and 3.3x for peers, the stock looks expensive on this metric, which can mean less room for error if expectations change.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages in the data so far? If you want to move quickly from headlines to your own judgement, consider both sides of the story with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Vera Therapeutics?

If you are serious about making your research count, do not stop at Vera Therapeutics. Use the Simply Wall St Screener to quickly surface fresh, high conviction ideas that match your style before other investors move first.

• Target potential mispricings by running through 44 high quality undervalued stocks that combine quality fundamentals with what could be attractive entry points.
• Strengthen your portfolio’s foundation by scanning solid balance sheet and fundamentals stocks screener (48 results) built around companies with healthier financial footing.
• Spot early opportunities by checking the screener containing 20 high quality undiscovered gems that the broader market may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.